Amarin (AMRN) Announce Encouraging Top Line Results
More News related to AMRN
- Amarin Corp Is First Small Biopharmaceutical Company to Join SAFE-BioPharma Association
- Amarin Appoints John F. Thero as Chief Financial Officer
- Amarin Announces Completion of $70 Million Private Placement
- Amarin Appoints Medpace as CRO for Two Phase 3 Cardiovascular Trials
- Amarin (AMRN) CEO Lynch To Step Down, Remains Chairman
Amarin Corporation plc (NASDAQ: AMRN) announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic autoimmune disease characterized by muscle weakness which can be life-threatening.
The primary objective of the exploratory study, for which interim results had previously been announced, was to assess the efficacy and safety of three doses of EN101 each given orally once daily for one week in patients with myasthenia gravis. The final results of the study indicate that 10mg, 20mg and 40mg of EN101 resulted in a statistically significant reduction in Quantitative Myasthenia Gravis (QMG) score from baseline of 11.8% (p=0.001), 16.8% (p<0.001) and 20.3% (p<0.001), respectively. Importantly, EN101 was also shown to be safe and well tolerated.
More from Release
Related Categories
FDAStocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
